France-based pharmaceutical company, Servier, has completed the acquisition of Denmark-based bioyechnology company, Symphogen A/S, it was reported on Thursday.

The acquisition means that Symphogen will function as Servier's antibody centre of excellence across multiple therapeutic areas, including oncology.

Christophe Thurieau, executive director of Servier Research Institute, has been named chief executive officer of Symphogen, and Karin Garre, former Symphogen chief operating officer, has been named general manager of Symphogen. Martin Olin, former Symphogen chief executive officer, is to act as the external consultant to support this deal.